前列腺特異性膜抗原 (PSMA) 診療整合市場報告 2025

近年來，前列腺特異性膜抗原（PSMA）診療試劑盒市場規模快速成長，預計將從2024年的9.2億美元成長到2025年的10.5億美元，複合年成長率（CAGR）為14.0%。過去幾年的成長主要受放射性藥物研發投入增加、前列腺癌發病率上升、放射化學試劑盒應用日益廣泛以及診斷監管核准擴大等因素的推動。

前列腺特異性膜抗原 (PSMA) 診療一體化試劑盒市場預計將在未來幾年快速成長，到 2029 年達到 17.5 億美元，複合年成長率 (CAGR) 為 13.7%。預測期內的成長將主要受以下因素驅動：對治療診斷學解決方案的需求不斷成長、分子影像報銷範圍擴大、製藥公司與學術機構合作日益密切以及短半衰期同位素的應用日益廣泛。預測期內的關鍵趨勢包括：試劑盒自動化技術的進步、PSMA 配體設計的創新、人工智慧在影像分析中的應用、同位素生產技術的進步以及伴隨診斷技術的開發進展。

前列腺癌發病率的不斷上升預計將推動前列腺特異性膜抗原 (PSMA) 診療一體化試劑盒市場在未來持續成長。攝護腺癌是一種發生於攝護腺的癌症，攝護腺是男性位於膀胱下方、直腸前方的小器官。前列腺癌病例的增加主要歸因於人口老化。隨著老齡化的成長，罹患此病的風險顯著增加。 PSMA 診療一體化試劑盒透過提供標靶診斷方案，在前列腺癌的診療管理中發揮重要作用，尤其適用於早期檢測和個人化治療方案的發展。這些試劑盒將 PSMA特異性配體與放射性示蹤劑結合，以提高診斷準確性，並增強疾病監測和治療指導。例如，根據美國非營利組織美國癌症協會於 2023 年 11 月發布的估計，到 2025 年，美國預計將新增約 313,780 例前列腺癌病例，並有 35,770 人死亡。因此，前列腺癌發病率的上升正在推動 PSMA 治療診斷試劑盒市場的成長。

為了滿足日益成長的精準癌症治療以及前列腺癌標靶診斷和治療的需求，PSMA標靶診療試劑盒市場的主要企業正致力於開發創新解決方案，例如PSMA標靶放射性配體試劑盒。 PSMA靶向放射性配體試劑盒將放射性同位素與一種旨在特異性結合PSMA的配體相結合，從而實現前列腺癌的診斷成像或標靶治療。例如，2025年3月，總部位於澳洲的放射性藥物公司Telix Pharmaceuticals Limited推出了創新試劑盒“Illuccix”，用於製備鎵-68戈澤肽注射。該試劑盒使醫院和核子醫學中心能夠在注射前立即標記放射性核素，用於對PSMA陽性前列腺癌病灶進行PET成像。此試劑盒的特點包括即用型、疾病特異性標靶化、快速成像以及與治療診斷流程的兼容性。這些優勢有助於更準確地檢測轉移性病灶、改善治療計劃並更有效地監測治療反應。與傳統的影像診斷和非標靶治療相比，它在診斷復發性和轉移性前列腺癌以及支持個人化治療策略的決策方面取得了顯著進展。

目錄

第1章執行摘要

第2章 市場特徵

第3章 市場趨勢與策略

第4章 市場：宏觀經濟情景，包括利率、通貨膨脹、地緣政治、貿易戰和關稅，以及新冠疫情及其復甦對市場的影響

第5章 全球成長分析與策略分析框架

• 全球前列腺特異性膜抗原 (PSMA) 診療試劑盒：PESTEL 分析（政治、社會、技術、環境、法律因素、促進因素和限制因素）
• 終端用戶產業分析
• 全球前列腺特異性膜抗原 (PSMA) 診療整合試劑盒市場：成長率分析
• 全球前列腺特異性膜抗原 (PSMA) 診療一體化試劑盒市場表現：規模與成長，2019-2024 年
• 全球前列腺特異性膜抗原 (PSMA) 診療一體化試劑盒市場預測：規模與成長，2024-2029 年，2034 年預測
• 全球前列腺特異性膜抗原 (PSMA) 診療試劑盒：潛在市場規模 (TAM)

第6章 市場細分

• 全球前列腺特異性膜抗原 (PSMA) 診療一體化試劑盒市場按產品類型、性能和預測分類，2019-2024 年、2024-2029 年預測、2034 年預測
• 診斷試劑盒
• 醫療包
• 複雜治療診斷試劑盒
• 全球前列腺特異性膜抗原 (PSMA) 診療一體化試劑盒市場：按應用、實際結果和預測分類，2019-2024 年、2024-2029 年預測、2034 年預測
• 攝護腺癌
• 其他癌症
• 全球前列腺特異性膜抗原 (PSMA) 診療一體化試劑盒市場：按最終用戶分類，實際值及預測值，2019-2024 年、2024-2029 年預測值、2034 年預測值
• 醫院
• 診斷中心
• 研究所
• 專科診所
• 其他
• 全球前列腺特異性膜抗原 (PSMA) 診療一體化試劑盒市場：按診斷試劑盒、類型、實際值和預測值細分，2019-2024 年、2024-2029 年預測值、2034 年預測值
• 前列腺特異性膜抗原 (PSMA) 正子斷層掃描 (PET) 影像試劑盒
• 單光子發射電腦斷層掃描（SPECT）成像套件
• 伴隨診斷試劑盒
• 液態生物檢體試劑盒
• 全球前列腺特異性膜抗原 (PSMA) 診療一體化試劑盒市場：按治療試劑盒、類型、性能和預測進行細分，2019-2024 年、2024-2029 年預測、2034 年預測
• 放射性配體治療試劑盒
• 抗體治療試劑盒
• 基於胜肽的治療試劑盒
• 小分子治療試劑盒
• 全球前列腺特異性膜抗原 (PSMA) 診療一體化試劑盒市場：依聯合診療一體化試劑盒類型細分，實際資料及預測資料（2019-2024 年、2024-2029 年預測值、2034 年預測值）。
• 整合成像和治療套件
• 雙功能放射性藥物試劑盒
• 基於前列腺特異性膜抗原 (PSMA) 配體的診療一體化試劑盒
• 個人化治療套裝

第7章 區域和國家分析

• 全球前列腺特異性膜抗原 (PSMA) 診療一體化試劑盒市場：按地區、績效和預測分類，2019-2024 年、2024-2029 年預測、2034 年預測
• 全球前列腺特異性膜抗原 (PSMA) 診療一體化試劑盒市場：按國家/地區分類，實際結果和預測，2019-2024 年、2024-2029 年預測、2034 年預測

第8章 亞太市場

第9章：中國市場

第10章 印度市場

第11章 日本市場

第12章：澳洲市場

第13章 印尼市場

第14章 韓國市場

第15章 西歐市場

第16章英國市場

第17章：德國市場

第18章：法國市場

第19章：義大利市場

第20章：西班牙市場

第21章 東歐市場

第22章 俄羅斯市場

第23章 北美市場

第24章美國市場

第25章：加拿大市場

第26章 南美洲市場

第27章：巴西市場

第28章 中東市場

第29章：非洲市場

第30章：競爭格局與公司概況

• 前列腺特異性膜抗原 (PSMA) 診療一體化試劑盒市場：競爭格局
• 前列腺特異性膜抗原（PSMA）診療一體化試劑盒市場：公司概況
  • Cyclotek（Aust）Pty Ltd Overview, Products and Services, Strategy and Financial Analysis
  • Telix Pharmaceuticals Ltd Overview, Products and Services, Strategy and Financial Analysis
  • Curium Pharma Overview, Products and Services, Strategy and Financial Analysis
  • SOFIE Biosciences Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Lantheus Holdings Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章：其他領先和創新企業

• Eckert & Ziegler SE
• CellBion Co. Ltd.
• NorthStar Medical Radioisotopes
• Isotopia Molecular Imaging Ltd
• ITM Isotope Technologies Munich SE
• Full-Life Technologies Ltd
• AdvanCell Pty Ltd
• Alpha-9 Theranostics Inc.
• ABX Advanced Biochemical Compounds GmbH
• Clarity Pharmaceuticals Ltd
• Ariceum Therapeutics GmbH
• Sinotau Pharmaceutical Group
• RadioMedix Inc.
• Scintomics GmbH
• FutureChem Co. Ltd.

第32章 全球市場競爭基準化分析與儀錶板

第33章 重大併購

第34章 近期市場趨勢

第35章：高潛力市場國家、細分市場與策略

• 2029年前列腺特異性膜抗原（PSMA）診療一體化試劑盒市場：提供新機會的國家
• 前列腺特異性膜抗原 (PSMA) 診療一體化試劑盒市場 2029 年展望：新興細分市場機會
• 前列腺特異性膜抗原 (PSMA) 診療一體化試劑盒市場 2029 年：成長策略
  • 基於市場趨勢的策略
  • 競爭對手策略

第36章附錄

Prostate-specific membrane antigen (PSMA) theranostic kits are specialized tools used to detect and treat prostate cancer by targeting the PSMA protein, which is highly expressed on cancer cells. They pair a PSMA-targeted imaging agent for precise tumor localization with a therapeutic component that delivers treatment directly to the cancer cells. These kits support personalized medicine by enhancing cancer staging, monitoring treatment response, and reducing harm to healthy tissue.

The main product types of prostate-specific membrane antigen (PSMA) theranostic kits include diagnostic kits, therapeutic kits, and combined theranostic kits. Diagnostic kits detect and visualize PSMA-expressing cancer cells using imaging agents, allowing accurate tumor localization, staging, and monitoring of prostate cancer. They are used in applications such as prostate cancer and other conditions, and serve end-users including hospitals, diagnostic centers, research institutes, specialty clinics, and others.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

The prostate-specific membrane antigen (PSMA) theranostic kits market research report is one of a series of new reports from The Business Research Company that provides prostate-specific membrane antigen (PSMA) theranostic kits market statistics, including prostate-specific membrane antigen (PSMA) theranostic kits industry global market size, regional shares, competitors with a prostate-specific membrane antigen (PSMA) theranostic kits market share, detailed prostate-specific membrane antigen (PSMA) theranostic kits market segments, market trends and opportunities, and any further data you may need to thrive in the prostate-specific membrane antigen (PSMA) theranostic kits industry. This prostate-specific membrane antigen (PSMA) theranostic kits market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The prostate-specific membrane antigen (PSMA) theranostic kits market size has grown rapidly in recent years. It will grow from $0.92 billion in 2024 to $1.05 billion in 2025 at a compound annual growth rate (CAGR) of 14.0%. The growth in the historic period was driven by growing investment in radiopharmaceutical research and development, the rising incidence of prostate cancer, increasing availability of radiochemistry kits, and expanding regulatory approvals for diagnostics.

The prostate-specific membrane antigen (PSMA) theranostic kits market size is expected to see rapid growth in the next few years. It will grow to $1.75 billion in 2029 at a compound annual growth rate (CAGR) of 13.7%. Growth in the forecast period will result from increasing demand for theranostic solutions, expanding reimbursement for molecular imaging, rising pharma-academic research collaborations, and wider availability of short-half-life isotopes. Major trends in the forecast period include technological advancements in kit automation, innovations in PSMA ligand design, AI integration for image analysis, advancements in isotope production, and progress in companion diagnostics development.

The increasing incidence of prostate cancer is expected to drive the growth of the prostate-specific membrane antigen (PSMA) theranostic kits market in the future. Prostate cancer is a type of cancer that develops in the prostate gland, a small organ in men located below the bladder and in front of the rectum. The rise in prostate cancer cases is largely due to the aging population, as the risk of developing the disease significantly increases with age. PSMA theranostic kits play a crucial role in managing prostate cancer by offering targeted diagnostic solutions, making them particularly effective for early detection and personalized treatment planning. These kits improve diagnostic accuracy by combining PSMA-specific ligands with radiotracers, enhancing disease monitoring and therapy guidance. For instance, in November 2023, the American Cancer Society, a U.S.-based nonprofit organization, estimated that approximately 313,780 new cases of prostate cancer and 35,770 deaths would occur in the United States in 2025. Therefore, the rising incidence of prostate cancer is driving the growth of the PSMA theranostic kits market.

Leading companies in the PSMA theranostic kits market are focusing on developing innovative solutions, such as PSMA-targeted radioligand kits, to meet the growing demand for precision oncology, targeted prostate cancer diagnosis, and therapy. PSMA-targeted radioligand kits combine a ligand designed to bind specifically to PSMA with a radioactive isotope for diagnostic imaging or targeted therapy of prostate cancer. For example, in March 2025, Telix Pharmaceuticals Limited, an Australia-based radiopharmaceutical company, launched Illuccix, an innovative kit for preparing Gallium-68 gozetotide injection. This kit allows hospitals and nuclear medicine facilities to label the radionuclide just before injection for PET imaging of PSMA-positive prostate cancer lesions. Unique features of the kit include its ready-to-use format, disease-specific targeting, rapid imaging capabilities, and compatibility with theranostic workflows. These advantages allow for better detection of metastatic lesions, improved treatment planning, and more effective monitoring of therapy responses. The kit's applications include diagnosing recurrent or metastatic prostate cancer and guiding personalized treatment decisions, offering a significant advancement over conventional imaging or non-targeted therapies.

In June 2023, Ariceum Therapeutics GmbH, a Germany-based biotech company, acquired Theragnostics Ltd. for an undisclosed amount. This acquisition was aimed at strengthening Ariceum Therapeutics' technological capabilities in PSMA-targeted theranostic kits and expanding its radiopharmaceutical portfolio for prostate cancer imaging. Theragnostics Ltd., a UK-based biopharmaceutical company, specializes in developing PSMA-targeted diagnostic kits, such as the 68Ga THP PSMA kit, for prostate cancer imaging.

Major companies operating in the prostate-specific membrane antigen (psma) theranostic kits market are Cyclotek (Aust) Pty Ltd, Telix Pharmaceuticals Ltd, Curium Pharma, SOFIE Biosciences Inc., Lantheus Holdings Inc., Eckert & Ziegler SE, CellBion Co. Ltd., NorthStar Medical Radioisotopes, Isotopia Molecular Imaging Ltd, ITM Isotope Technologies Munich SE, Full-Life Technologies Ltd, AdvanCell Pty Ltd, Alpha-9 Theranostics Inc., ABX Advanced Biochemical Compounds GmbH, Clarity Pharmaceuticals Ltd, Ariceum Therapeutics GmbH, Sinotau Pharmaceutical Group, RadioMedix Inc., Scintomics GmbH, FutureChem Co. Ltd.

North America was the largest region in the prostate-specific membrane antigen (PSMA) theranostic kits market in 2024. The regions covered in prostate-specific membrane antigen (PSMA) theranostic kits report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the prostate-specific membrane antigen (PSMA) theranostic kitsprostate-specific membrane antigen (PSMA) theranostic kits market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The prostate-specific membrane antigen (PSMA) theranostic kits market consists of sales of radiolabeled therapeutic agents, diagnostic kits, combination theranostic kits, antibody-based PSMA theranostics, PSMA ligand-based drug conjugates, and companion diagnostic kits. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on prostate-specific membrane antigen (psma) theranostic kits market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for prostate-specific membrane antigen (psma) theranostic kits ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The prostate-specific membrane antigen (psma) theranostic kits market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product Type: Diagnostic Kits; Therapeutic Kits; Combined Theranostic Kits
• 2) By Application: Prostate Cancer; Other Cancers
• 3) By End-User: Hospitals; Diagnostic Centers; Research Institutes; Specialty Clinics; Others
• Subsegments:
• 1) By Diagnostic Kits: Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography Imaging Kits; Single Photon Emission Computed Tomography Imaging Kits; Companion Diagnostic Kits; Liquid Biopsy Kits
• 2) By Therapeutic Kits: Radioligand Therapy Kits; Antibody-Based Therapy Kits; Peptide-Based Therapy Kits; Small Molecule Therapy Kits
• 3) By Combined Theranostic Kits: Integrated Imaging And Therapy Kits; Dual Function Radiopharmaceutical Kits; Prostate-Specific Membrane Antigen (PSMA) Ligand-Based Theranostic Kits; Personalized Treatment Kits
• Companies Mentioned: Cyclotek (Aust) Pty Ltd; Telix Pharmaceuticals Ltd; Curium Pharma; SOFIE Biosciences Inc.; Lantheus Holdings Inc.; Eckert & Ziegler SE; CellBion Co. Ltd.; NorthStar Medical Radioisotopes; Isotopia Molecular Imaging Ltd; ITM Isotope Technologies Munich SE; Full-Life Technologies Ltd; AdvanCell Pty Ltd; Alpha-9 Theranostics Inc.; ABX Advanced Biochemical Compounds GmbH; Clarity Pharmaceuticals Ltd; Ariceum Therapeutics GmbH; Sinotau Pharmaceutical Group; RadioMedix Inc.; Scintomics GmbH; FutureChem Co. Ltd.
• Countries:

Table of Contents

1. Executive Summary

2. Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market Characteristics

3. Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market Trends And Strategies

4. Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

• 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Growth Analysis And Strategic Analysis Framework

• 5.1. Global Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market Growth Rate Analysis
• 5.4. Global Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Total Addressable Market (TAM)

6. Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market Segmentation

• 6.1. Global Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Diagnostic Kits
• Therapeutic Kits
• Combined Theranostic Kits
• 6.2. Global Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Prostate Cancer
• Other Cancers
• 6.3. Global Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Diagnostic Centers
• Research Institutes
• Specialty Clinics
• Others
• 6.4. Global Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Sub-Segmentation Of Diagnostic Kits, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography Imaging Kits
• Single Photon Emission Computed Tomography Imaging Kits
• Companion Diagnostic Kits
• Liquid Biopsy Kits
• 6.5. Global Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Sub-Segmentation Of Therapeutic Kits, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Radioligand Therapy Kits
• Antibody Based Therapy Kits
• Peptide Based Therapy Kits
• Small Molecule Therapy Kits
• 6.6. Global Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Sub-Segmentation Of Combined Theranostic Kits, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Integrated Imaging And Therapy Kits
• Dual Function Radiopharmaceutical Kits
• Prostate-Specific Membrane Antigen (PSMA) Ligand Based Theranostic Kits
• Personalized Treatment Kits

7. Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market Regional And Country Analysis

• 7.1. Global Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market

• 8.1. Asia-Pacific Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market

• 9.1. China Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market Overview
• 9.2. China Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market

• 10.1. India Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market

• 11.1. Japan Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market Overview
• 11.2. Japan Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market

• 12.1. Australia Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market

• 13.1. Indonesia Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market

• 14.1. South Korea Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market Overview
• 14.2. South Korea Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market

• 15.1. Western Europe Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market Overview
• 15.2. Western Europe Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market

• 16.1. UK Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market

• 17.1. Germany Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market

• 18.1. France Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market

• 19.1. Italy Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market

• 20.1. Spain Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market

• 21.1. Eastern Europe Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market Overview
• 21.2. Eastern Europe Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market

• 22.1. Russia Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market

• 23.1. North America Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market Overview
• 23.2. North America Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market

• 24.1. USA Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market Overview
• 24.2. USA Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market

• 25.1. Canada Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market Overview
• 25.2. Canada Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market

• 26.1. South America Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market Overview
• 26.2. South America Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market

• 27.1. Brazil Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market

• 28.1. Middle East Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market Overview
• 28.2. Middle East Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market

• 29.1. Africa Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market Overview
• 29.2. Africa Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market Competitive Landscape And Company Profiles

• 30.1. Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market Competitive Landscape
• 30.2. Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market Company Profiles
  • 30.2.1. Cyclotek (Aust) Pty Ltd Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Telix Pharmaceuticals Ltd Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Curium Pharma Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. SOFIE Biosciences Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Lantheus Holdings Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market Other Major And Innovative Companies

• 31.1. Eckert & Ziegler SE
• 31.2. CellBion Co. Ltd.
• 31.3. NorthStar Medical Radioisotopes
• 31.4. Isotopia Molecular Imaging Ltd
• 31.5. ITM Isotope Technologies Munich SE
• 31.6. Full-Life Technologies Ltd
• 31.7. AdvanCell Pty Ltd
• 31.8. Alpha-9 Theranostics Inc.
• 31.9. ABX Advanced Biochemical Compounds GmbH
• 31.10. Clarity Pharmaceuticals Ltd
• 31.11. Ariceum Therapeutics GmbH
• 31.12. Sinotau Pharmaceutical Group
• 31.13. RadioMedix Inc.
• 31.14. Scintomics GmbH
• 31.15. FutureChem Co. Ltd.

32. Global Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market

34. Recent Developments In The Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market

35. Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market High Potential Countries, Segments and Strategies

• 35.1 Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer